1. Home
  2. NBY vs PHGE Comparison

NBY vs PHGE Comparison

Compare NBY & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

HOLD

Current Price

$1.07

Market Cap

6.3M

Sector

N/A

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$4.59

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBY
PHGE
Founded
2000
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
6.9M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
NBY
PHGE
Price
$1.07
$4.59
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
116.4K
62.5K
Earning Date
11-07-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$10,302,000.00
N/A
Revenue This Year
$23.91
N/A
Revenue Next Year
$32.05
N/A
P/E Ratio
$41.19
N/A
Revenue Growth
390.34
N/A
52 Week Low
$0.46
$4.10
52 Week High
$4.44
$22.06

Technical Indicators

Market Signals
Indicator
NBY
PHGE
Relative Strength Index (RSI) 48.92 74.68
Support Level $1.00 $4.10
Resistance Level $1.11 $4.91
Average True Range (ATR) 0.09 0.30
MACD 0.02 0.39
Stochastic Oscillator 84.28 77.56

Price Performance

Historical Comparison
NBY
PHGE

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: